Therapeutic Target Details
| Target ID: | T06 |
| Target Name: | Glucagon-like peptide 1 receptor |
| Synonyms: | GLP1R; GLP-1; GLP-1 receptor |
| GENE: | GLP1R |
| Action: | agonist |
| Class: | GPCR |
| UniProtKB ID: | P43220 |
| Entry Name: | GLP1R_HUMAN |
| Related Drugs: | Dulaglutide; Exenatide; Glucagon; Liraglutide; Semaglutide |
| Mechanism: | Glucagon-like peptide 1 (GLP-1) analogues have been reported to be involved in weight loss and systemic insulin resistance reduction, which may lead to improvements in NAFLD. GLP-1 analogues may also act directly on human hepatocytes to decrease de novo adipogenesis and increase fatty acid oxidation, thereby ameliorating NAFLD. |
| Reference (PMIDs): | 20225248 |
| Drug ID | Drug Name | Type | DrugBank ID | Targets | Category | Latest Progress | |
|---|---|---|---|---|---|---|---|
| D116 | Dulaglutide | Biological drug | DB09045 | GLP1R agonist | Improve insulin resistance | Under clinical trials | Details |
| D129 | Exenatide | Biological drug | DB01276 | GLP1R activator; GLP1R agonist | Improve insulin resistance | Under clinical trials | Details |
| D155 | Glucagon | Biological drug | DB00040 | GCGR agonist | Antidiabetic drug | Under clinical trials | Details |
| D207 | Liraglutide | Biological drug | DB06655 | GLP1R activator; GLP1R agonist; GCG receptor antagonist activity | Improve insulin resistance | Under clinical trials | Details |
| D327 | Semaglutide | Chemical drug | DB13928 | GLP1R agonist | Antidiabetic drug | Under clinical trials | Details |
| Candidate ID | Source ID | Source Type | Compound Type | Candidate Name | Inclusion Criteria | |
|---|---|---|---|---|---|---|
| R1200 | DB09043 | approved | biotech | Albiglutide | Target associated | Details |
| R1275 | DB09265 | approved | small molecule | Lixisenatide | Target associated | Details |
| R1607 | DB16697 | investigational | biotech | Glutazumab | Target associated | Details |
| Compound ID | Source ID | Source Type | Compound Name | Molecular Weight | Molecular Formula | Molecular Species | |
|---|---|---|---|---|---|---|---|
| B000026 | CHEMBL1010 | Small molecule | CEFOTAXIME SODIUM | 477.46 | C16H16N5NaO7S2 | ACID | Details |
| B000059 | CHEMBL1018 | Small molecule | DIENESTROL | 266.34 | C18H18O2 | NEUTRAL | Details |
| B000060 | CHEMBL101815 | Small molecule | -- | 225.21 | C12H7N3O2 | NEUTRAL | Details |
| B000074 | CHEMBL102397 | Small molecule | -- | 291.27 | C12H13N5O4 | NEUTRAL | Details |
| B000080 | CHEMBL102714 | Small molecule | SB-216763 | 371.22 | C19H12Cl2N2O2 | NEUTRAL | Details |
| B000083 | CHEMBL103 | Small molecule | PROGESTERONE | 314.47 | C21H30O2 | NEUTRAL | Details |
| B000091 | CHEMBL103583 | Small molecule | -- | 217.27 | C16H11N | NEUTRAL | Details |
| B000093 | CHEMBL1036 | Small molecule | HYDROXYHALOPERIDOL | 377.89 | C21H25ClFNO2 | BASE | Details |
| B000101 | CHEMBL104 | Small molecule | CLOTRIMAZOLE | 344.85 | C22H17ClN2 | NEUTRAL | Details |
| B000107 | CHEMBL104255 | Small molecule | FLAVOKAWAIN B | 284.31 | C17H16O4 | NEUTRAL | Details |
| Article ID | PMID | Source | Title | |
|---|---|---|---|---|
| A00391 | 35104330 | Diabetes Care | Glucagon-Like Peptide 1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors and Risk of Nonalcoholic Fatty Liver Disease Among Patients With Type 2 Diabetes. | Details |
| A00971 | 34915054 | J Hepatol | A structurally engineered fatty acid, icosabutate, suppresses liver inflammation and fibrosis in NASH. | Details |
| A01097 | 34870138 | Metabol Open | Metabolic causes and consequences of nonalcoholic fatty liver disease (NAFLD). | Details |
| A01147 | 34855339 | FP Essent | Liver Disease: Nonalcoholic Fatty Liver Disease. | Details |
| A01387 | 34764398 | Sci Rep | A meta-analysis of the effects of glucagon-like-peptide 1 receptor agonist (GLP1-RA) in nonalcoholic fatty liver disease (NAFLD) with type 2 diabetes (T2D). | Details |
| A01761 | 34627692 | Nutr Metab Cardiovasc Dis | Beneficial effects of glucagon-like peptide 1 receptor agonists on glucose control, cardiovascular risk profile, and non-alcoholic fatty liver disease. An expert opinion of the Italian diabetes society. | Details |
| A02330 | 34416040 | Aliment Pharmacol Ther | Review article: non-alcoholic fatty liver disease and cardiovascular diseases: associations and treatment considerations. | Details |
| A02574 | 34326020 | Surg Obes Relat Dis | Metabolic surgery may protect against admission for COVID-19 in persons with nonalcoholic fatty liver disease. | Details |
| A02857 | 34214406 | Expert Opin Investig Drugs | Anti-diabetic drugs and NASH: from current options to promising perspectives. | Details |
| A03040 | 34155798 | Liver Int | Non-alcoholic fatty liver disease in type 2 diabetes - A specific entity? | Details |
| A06026 | 33036179 | J Clin Med | One Year's Treatment with the Glucagon-Like Peptide 1 Receptor Agonist Liraglutide Decreases Hepatic Fat Content in Women with Nonalcoholic Fatty Liver Disease and Prior Gestational Diabetes Mellitus in a Randomized, Placebo-Controlled Trial. | Details |
| A06074 | 33015726 | Curr Diab Rep | Role of Agents for the Treatment of Diabetes in the Management of Nonalcoholic Fatty Liver Disease. | Details |
| A07241 | 32571083 | Ann Pharmacother | A Systematic Review of Newer Antidiabetic Agents in the Treatment of Nonalcoholic Fatty Liver Disease. | Details |
| A07430 | 32502637 | Pharmacol Res | Molecular mechanisms of hepatic insulin resistance in nonalcoholic fatty liver disease and potential treatment strategies. | Details |
| A07440 | 32496108 | Rev Esp Enferm Dig | The efficacy of glucagon-like peptide 1 receptor agonists in patients with non-alcoholic fatty liver disease: a systematic review and meta-analysis of randomized controlled trials. | Details |
| A07629 | 32414752 | BMJ Open Gastroenterol | Spatial expression of glucagon-like peptide 1 receptor and caveolin-1 in hepatocytes with macrovesicular steatosis in non-alcoholic steatohepatitis. | Details |
| A07979 | 32291277 | Diabetes Care | Effects of Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide on Biomarkers of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes. | Details |
| A08701 | 32017891 | Am J Med | Nonalcoholic Fatty Liver Disease: What Does the Primary Care Physician Need to Know? | Details |
| A10476 | 31321014 | Ther Adv Chronic Dis | Effects of glucagon-like peptide 1 receptor agonists on comorbidities in older patients with diabetes mellitus. | Details |
| A12223 | 30556145 | Hepatology | Modulation of Insulin Resistance in Nonalcoholic Fatty Liver Disease. | Details |